Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

NCT07222917 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07222917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07222917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 5, 2025
Completion date
December 10, 2026
Enrollment
222 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease and hypertension